http://www.sciencedaily.com/releases/2011/09/110902133047.htm
"Low-Dose Naltrexone (LDN): Tricking the Body to Heal Itself
ScienceDaily (Sep. 2, 2011) Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered the mechanism by which a low dose of the opioid antagonist naltrexone (LDN), an agent used clinically (off-label) to treat cancer and autoimmune diseases, exerts a profound inhibitory effect on cell proliferation.
....LDN has proven successful in Phase I and II clinical trials in the treatment of Crohn's disease, and OGF (opoid growth factor) has been reported to be safe and efficacious for the treatment of advanced pancreatic cancer.
....Dr. Donahue, who has devoted a concentrated effort on improving the health of women through research explains: "This study joins a series of other investigations ... demonstrating that both LDN and OGF offer powerful treatments to combat a devastating cancer that strikes over 20,000 women in the U.S. each year and stands as the 5th leading cause of cancer-related deaths in females. Thus, one should not lose sight that the OGF-OGFr axis is a new frontier in understanding the pathogenesis and treatment of a cancer that has been, up to now, recalcitrant to conventional therapies."